secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001193125-24-194427
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm Q2 revenue $42.8M, net income $23.8M on debt gain; raises FY guidance low end
--------------------------------------------------------------------------------

- Q2 2024 total revenue $42.8M (Q2 2023: $37.6M); US XPOVIO net product revenue $28.0M (Q2 2023: $28.5M).
- Net income $23.8M ($0.15 basic EPS) vs net loss $32.6M in Q2 2023; includes $44.7M non-cash gain on debt extinguishment.
- Raises FY2024 total revenue guidance low end to $145M from $140M; lowers R&D/SG&A expense guidance to $250-265M from $260-280M.
- Phase 3 SENTRY (myelofibrosis) top-line data on track for 2H 2025; XPORT-EC-042 (endometrial) top-line delayed to early 2026 due to screen failures.
- Debt refinancing extended majority of maturities to 2028/2029; cash $152.5M; cash runway into Q1 2026 (excl. $49.5M debt payments).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524194427/0001193125-24-194427-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524194427/d878101d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-194427

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer